{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:03Z","timestamp":1761059103735,"version":"3.38.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T00:00:00Z","timestamp":1283990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11886-010-0140-7","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T05:35:44Z","timestamp":1283924144000},"page":"450-463","source":"Crossref","is-referenced-by-count":7,"title":["Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?"],"prefix":"10.1007","volume":"12","author":[{"given":"Sulaf J.","family":"Mansur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi G.","family":"Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,9]]},"reference":[{"key":"140_CR1","first-page":"459","volume":"5","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Oparil S: Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Ther Clin Risk Manag 2009, 5:459\u2013464.","journal-title":"Ther Clin Risk Manag"},{"key":"140_CR2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","volume":"109","author":"G Nguyen","year":"2002","unstructured":"Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417\u20131427.","journal-title":"J Clin Invest"},{"key":"140_CR3","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","volume":"20","author":"S Johar","year":"2006","unstructured":"Johar S, Cave AC, Narayanapanicker A, et al.: Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006, 20:1546\u20131548.","journal-title":"FASEB J"},{"key":"140_CR4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3949\/ccjm.76a.09030","volume":"76","author":"Q Che","year":"2009","unstructured":"Che Q, Schreiber MJ Jr, Rafey MA: Beta-blockers for hypertension: are they going out of style? Cleve Clinic J Med 2009, 76:533\u2013542.","journal-title":"Cleve Clinic J Med"},{"key":"140_CR5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","volume":"106","author":"R Candido","year":"2002","unstructured":"Candido R, Jandeleit-Dahm KA, Cao Z, et al.: Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246\u2013253.","journal-title":"Circulation"},{"key":"140_CR6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.CIR.101.13.1586","volume":"101","author":"WB Strawn","year":"2000","unstructured":"Strawn WB, Chappell MC, Dean RH, et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1586\u20131593.","journal-title":"Circulation"},{"key":"140_CR7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0022-3565(25)11459-6","volume":"260","author":"CT Stier Jr","year":"1992","unstructured":"Stier CT Jr, Mahboubi K, DiPippo VA, et al.: The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. J Pharmacol Exp Ther 1992, 260:1410\u20131415.","journal-title":"J Pharmacol Exp Ther"},{"key":"140_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/hr.2009.184","volume":"33","author":"K Hanif","year":"2010","unstructured":"Hanif K, Bid HK, Konwar R: Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res 2010, 33:11\u201321.","journal-title":"Hypertens Res"},{"key":"140_CR9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.1996.03530430051039","volume":"275","author":"RE Schmieder","year":"1996","unstructured":"Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507\u20131513.","journal-title":"JAMA"},{"key":"140_CR10","first-page":"145","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145\u2013153.","journal-title":"The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med"},{"key":"140_CR11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61193-9","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo K, Anderson C, et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174\u20131183.","journal-title":"Lancet"},{"key":"140_CR12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"\u2022 Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547\u20131559. The ONTARGET study showed in more than 25,000 patients at high risk for cardiovascular disease that the ACEI\/ARB combination is not superior to ACEI monotherapy but is associated with a higher rate of adverse events.","journal-title":"N Engl J Med"},{"key":"140_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cpcardiol.2008.10.002","volume":"34","author":"KK Gaddam","year":"2009","unstructured":"Gaddam KK, Pimenta E, Husain S, Calhoun DA: Aldosterone and cardiovascular disease. Current Probl Cardiol 2009, 34:51\u201384.","journal-title":"Current Probl Cardiol"},{"key":"140_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ccl.2008.06.003","volume":"26","author":"E Pimenta","year":"2008","unstructured":"Pimenta E, Oparil S: Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? Cardiol Clin 2008, 26:527\u2013535.","journal-title":"Cardiol Clin"},{"key":"140_CR15","first-page":"45","volume":"7","author":"MA Weber","year":"2006","unstructured":"Weber MA, Giles TD: Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006, 7:45\u201354.","journal-title":"Rev Cardiovasc Med"},{"key":"140_CR16","first-page":"803","volume":"10","author":"AH Meiracker van den","year":"1992","unstructured":"van den Meiracker AH, Man in \u2019t Veld AJ, Admiraal PJ, et al.: Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992, 10:803\u2013812.","journal-title":"J Hypertens"},{"key":"140_CR17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199002000-00015","volume":"15","author":"V Mooser","year":"1990","unstructured":"Mooser V, Nussberger J, Juillerat L, et al.: Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990, 15:276\u2013282.","journal-title":"J Cardiovasc Pharmacol"},{"key":"140_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract 2007, 3:486\u2013492.","journal-title":"Nat Clin Pract"},{"key":"140_CR19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/ajh.2009.138","volume":"22","author":"AS Bomback","year":"2009","unstructured":"Bomback AS, Toto R: Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. American journal of hypertension 2009, 22:1032\u20131040.","journal-title":"American journal of hypertension"},{"key":"140_CR20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","volume":"8","author":"Y Uresin","year":"2007","unstructured":"Uresin Y, Taylor AA, Kilo C, et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007, 8:190\u2013198.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"140_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","volume":"52","author":"DL Feldman","year":"2008","unstructured":"Feldman DL, Jin L, Xuan H, et al.: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130\u2013136.","journal-title":"Hypertension"},{"key":"140_CR22","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510\u2013e526.","journal-title":"Circulation"},{"key":"140_CR23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290\u2013300.","journal-title":"Am J Med"},{"key":"140_CR24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","volume":"45","author":"TW Doulton","year":"2005","unstructured":"Doulton TW, He FJ, MacGregor GA: Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45:880\u2013886.","journal-title":"Hypertension"},{"key":"140_CR25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","volume":"28","author":"NH Andersen","year":"2005","unstructured":"Andersen NH, Poulsen PL, Knudsen ST, et al.: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005, 28:273\u2013277.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"140_CR26","doi-asserted-by":"crossref","first-page":"39A","DOI":"10.1177\/14732300050330S106","volume":"33","author":"I Petrovic","year":"2005","unstructured":"Petrovic I, Petrovic D, Vukovic N, et al.: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and\/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005, 33(Suppl 1):39A\u201349A.","journal-title":"J Int Med Res"},{"key":"140_CR27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0828-282X(10)70377-9","volume":"26","author":"NR Campbell","year":"2010","unstructured":"Campbell NR, Kaczorowski J, Lewanczuk RZ, et al.: 2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol 26:236\u2013240.","journal-title":"Can J Cardiol"},{"key":"140_CR28","doi-asserted-by":"crossref","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Oct 15 [Epub ahead of print].","DOI":"10.1097\/HJH.0b013e328333146d"},{"key":"140_CR29","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","volume":"39","author":"J Nussberger","year":"2002","unstructured":"Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1\u2013E8.","journal-title":"Hypertension"},{"key":"140_CR30","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","volume":"15","author":"M Azizi","year":"2004","unstructured":"Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15:3126\u20133133.","journal-title":"J Am Soc Nephrol"},{"key":"140_CR31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S Oparil","year":"2007","unstructured":"\u2022 Oparil S, Yarows SA, Patel S, et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221\u2013229. This large randomized study established the additive BP-lowering effect of a DRI to an ARB.","journal-title":"Lancet"},{"key":"140_CR32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","volume":"20","author":"JL Pool","year":"2007","unstructured":"Pool JL, Schmieder RE, Azizi M, et al.: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007, 20:11\u201320.","journal-title":"Am J Hypertens"},{"key":"140_CR33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1185\/030079908X280581","volume":"24","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, Murray AV, Hoppe UC, et al.: Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008, 24:1039\u20131047.","journal-title":"Curr Med Res Opin"},{"issue":"11 Pt 1","key":"140_CR34","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16(11 Pt 1):925\u2013930.","journal-title":"Am J Hypertens"},{"key":"140_CR35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839\u2013845.","journal-title":"Hypertension"},{"key":"140_CR36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F Souza de","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G: Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147\u2013152.","journal-title":"Hypertension"},{"key":"140_CR37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893\u20131906.","journal-title":"N Engl J Med"},{"key":"140_CR38","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","volume":"111","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Skali H, Anavekar NS, et al.: Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005, 111:3411\u20133419.","journal-title":"Circulation"},{"key":"140_CR39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","volume":"119","author":"SD Solomon","year":"2009","unstructured":"Solomon SD, Appelbaum E, Manning WJ, et al.: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530\u2013537.","journal-title":"Circulation"},{"key":"140_CR40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"140_CR41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"SA Hunt","year":"2009","unstructured":"Hunt SA, Abraham WT, Chin MH, et al.: 2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1\u2013e90.","journal-title":"J Am Coll Cardiol"},{"key":"140_CR42","first-page":"1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056\u20131064.","journal-title":"The RESOLVD Pilot Study Investigators. Circulation"},{"key":"140_CR43","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767\u2013771.","journal-title":"Lancet"},{"key":"140_CR44","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667\u20131675.","journal-title":"N Engl J Med"},{"key":"140_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"JJ McMurray","year":"2008","unstructured":"McMurray JJ, Pitt B, Latini R, et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17\u201324.","journal-title":"Circ Heart Fail"},{"key":"140_CR46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"140_CR47","doi-asserted-by":"crossref","unstructured":"Kidney Disease Outcomes Quality Initiative (K\/DOQI): K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 Suppl 1):S1\u2013S290.","DOI":"10.1053\/j.ajkd.2004.03.003"},{"issue":"12 Suppl 3","key":"140_CR48","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1681\/ASN.2006080922","volume":"17","author":"G Fernandez-Juarez","year":"2006","unstructured":"Fernandez-Juarez G, Barrio V, de Vinuesa SG, et al.: Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006, 17(12 Suppl 3):S250\u2013S254.","journal-title":"J Am Soc Nephrol"},{"key":"140_CR49","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440\u20131444.","journal-title":"BMJ"},{"key":"140_CR50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30\u201348.","journal-title":"Ann Intern Med"},{"key":"140_CR51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547\u2013553.","journal-title":"Lancet"},{"key":"140_CR52","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","volume":"72","author":"GL Bakris","year":"2007","unstructured":"Bakris GL, Ruilope L, Locatelli F, et al.: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007, 72:879\u2013885.","journal-title":"Kidney Int"},{"key":"140_CR53","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"\u2022 Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433\u20132446. The AVOID trial showed that the addition of a DRI to an ARB doubled the proportion of patients with greater than 50% reduction in albuminuria in response to therapy.","journal-title":"N Engl J Med"},{"key":"140_CR54","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:542\u2013551.","journal-title":"Clin J Am Soc Nephrol"},{"key":"140_CR55","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","volume":"24","author":"HH Parving","year":"2009","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663\u20131671.","journal-title":"Nephrol Dial Transplant"},{"key":"140_CR56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123.","journal-title":"Hypertension"},{"key":"140_CR57","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","volume":"32","author":"F Persson","year":"2009","unstructured":"Persson F, Rossing P, Reinhard H, et al.: Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32:1873\u20131879.","journal-title":"Diabetes Care"},{"key":"140_CR58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","volume":"4","author":"LF Fried","year":"2009","unstructured":"Fried LF, Duckworth W, Zhang JH, et al.: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4:361\u2013368.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-010-0140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-010-0140-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-010-0140-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:51:19Z","timestamp":1740502279000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-010-0140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,9]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s11886-010-0140-7","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2010,9,9]]}}}